Novavax Inc. (NVAX)
| Bid | 6.35 |
| Market Cap | 1.03B |
| Revenue (ttm) | 682.16M |
| Net Income (ttm) | -187.5M |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | -5.22 |
| Forward PE | 12.14 |
| Analyst | Hold |
| Ask | 6.65 |
| Volume | 4,977,698 |
| Avg. Volume (20D) | 5,177,578 |
| Open | 6.63 |
| Previous Close | 6.67 |
| Day's Range | 6.28 - 6.57 |
| 52-Week Range | 4.43 - 23.86 |
| Beta | 3.14 |
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria...
Analyst Forecast
According to 6 analyst ratings, the average rating for NVAX stock is "Hold." The 12-month stock price forecast is $18.5, which is an increase of 188.39% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago · proactiveinvestors.com
Novavax shares jump as FDA signals path to COVID vaccine approvalNovavax, Inc. (NASDAQ:NVAX) shares surged more than 16% after the company shared a positive update on its COVID-19 vaccine, which it believes is “approvable” based on its conversations with the US Foo...
